NCT00464776View on ClinicalTrials.gov

Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

April 30, 2008

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Aliskiren

DRUG

Aliskiren

DRUG

Aliskiren

DRUG

Aliskiren

Trial Locations (1)

2820

Novartis, Gentofte Municipality

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00464776 - Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy | Biotech Hunter | Biotech Hunter